The First Wave — Resveratrol as a Direct Sirtuin Activator
Early reports suggested resveratrol directly boosted SIRT1 activity.
- 2003: Reported year (Placeholder citation marker)
- Cell-free: Assay type (Fluorogenic substrate)
- ~13x: Claimed fold-activation (Placeholder figure)
- High: Initial excitement (Placeholder note)
Original activation claim
Placeholder: cell-free fluorogenic assay reported large SIRT1 activation.
Rapid scientific and media interest
Placeholder: findings drew broad attention across longevity research.
The Fluorophore Problem — Questioning the Original Assay
Follow-up work found the assay dye itself was driving the signal.
- Dye-linked peptide: Artifact source (Placeholder detail)
- Much weaker: Native substrate result (Placeholder figure)
- 2005: Key rebuttal year (Placeholder citation marker)
- Controversy: Field reaction (Placeholder note)
Dye-dependent signal discovered
Placeholder: activation seen only with fluorophore-conjugated substrate.
Native peptide re-testing
Placeholder: unlabeled substrate assays showed minimal direct activation.
Getting There — The Oral Bioavailability Problem
Resveratrol is metabolized rapidly, limiting active plasma exposure.
- <1%: Oral bioavailability (Placeholder figure)
- Glucuronidation: Main metabolism route (Placeholder detail)
- Short: Plasma half-life (Placeholder note)
- High: Dose needed (animal) (Placeholder figure)
Rapid first-pass metabolism
Placeholder: gut and liver conjugation clears resveratrol quickly.
Implications for dosing
Placeholder: high oral doses required to reach effective tissue levels.
Inconsistent Outcomes Across Later Trials
Subsequent animal and human studies produced inconsistent effects.
- Some: Positive animal studies (Placeholder figure)
- Mixed: Human trial outcomes (Placeholder note)
- Small/variable: Effect size (Placeholder detail)
- Inconclusive: Meta-analyses (Placeholder note)
Variable trial designs
Placeholder: differing doses and endpoints hindered comparison.
Reassessing the sirtuin hypothesis
Placeholder: doubts grew about direct allosteric SIRT1 activation.
Next-Generation Sirtuin-Activating Compounds
Newer STAC molecules were engineered for potency and delivery.
- STACs: New compound class (Placeholder detail)
- ~1000x: Potency improvement (Placeholder figure)
- Improved: Bioavailability fix (Placeholder note)
- Ongoing trials: Clinical status (Placeholder note)
Rational compound redesign
Placeholder: structure-based design improved activator specificity.
Where the field stands now
Placeholder: cautious optimism replaces early overstated claims.
Placeholder: lessons from resveratrol reshaped sirtuin drug development.